Experiment Overview
| Repository ID: | FR-FCM-Z57G | Experiment name: | Venetoclax treatment in AML patients has limited impact on circulating T and NK cells | MIFlowCyt score: | 83.75% |
| Primary researcher: | Charis Teh | PI/manager: | Charis Teh | Uploaded by: | Charis Teh |
| Experiment dates: | 2019-11-01 - 2022-03-31 | Dataset uploaded: | Apr 2022 | Last updated: | May 2022 |
| Keywords: | [mass cytometry] [AML] [venetoclax] | Manuscripts: | |||
| Organizations: |
The Walter and Eliza Hall Institute of Medical Research, Immunology, Melbourne, VIC3052 (Australia)
|
||||
| Purpose: | To profile circulating blood cells from three cohorts of cancer patients before and after treatment with venetoclax using mass cytometry (CyTOF) or flow cytometry Cohort 1: Chronic lymphocytic leukemia (CLL) - mass cytometry Cohort 2: Acute myeloid leukemia (AML) - mass cytometry Cohort 3: Breast cancer - flow cytometry | ||||
| Conclusion: | Venetoclax has minimal impact on circulating T or NK cells | ||||
| Comments: | None | ||||
| Funding: | This work was supported by: an Australian NHMRC Fellowships 1089072 (C.E.T), 1090236 and 1158024 (D.H.D.G), 1078730 and 1175960 (G.J.L); a Fulbright Australia-America Postdoctoral Fellowship (C.E.T); a Victorian Cancer Agency Mid-Career Fellowship MCRF20026 (C.E.T); Cancer Council of Victoria Grants-in-Aid 1146518 and 1102104 (D.H.D.G); Perpetual Impact Philanthropy Founding (C.E.T.); Australian NHRMC grants 2002618 (C.E.T), 1113577, 1016701, 1079560 (A.W.R/D.C.S.H); 1113133, 1153049 (G.J.L), the Metcalf Family (A.H.W); the Leukemia and Lymphoma Society, US, Specialized Center of Research [SCOR] grant 7015-18 (A.H.W); a Medical Research Future Fund grant 1141460 (A.H.W.); National Breast Cancer Foundation Australia IIRS-19-004; Breast Cancer Research Foundation (BCRF-20-182) (G.J.L), Investigator Initiated Study support from AbbVie and Genentech (Roche) for the mBEP study (ACTRN12615000702516) (G.J.L). | ||||
| Quality control: | - An anchor healthy blood sample is used in each run - All antibodies were titrated to determine ideal concentrations of used - Where samples needed to be ran in two batches on different days, cytometers with the same settings were used. | ||||
Experiment variables
| Conditions | |
|---|---|
| · pre-venetoclax | AML_CAL-018_SCR.fcs · AML_CAL-019_SCR.fcs · AML_CAL-023_SCR.fcs · AML_CAL-026_SCR.fcs · AML_CAL-027_SCR.fcs · AML_CAL-033_SCR.fcs · AML_CAL-036_SCR.fcs · AML_CVC-002_SCR.fcs · AML_CVC-005_SCR.fcs · AML_CAL016 (SCAL020)_SCR.fcs · AML_CAL043 (SCAL055)_SCR.fcs · AML_CAL044 (SCAL056)_SCR.fcs · AML_CAU008_SCR.fcs · AML_CBH002_SCR.fcs · AML_CVC-002_SCR.fcs-(1) · AML_CVC001_SCR.fcs |
| · post-venetoclax | AML_CAL-018_D7.fcs · AML_CAL-019_D7.fcs · AML_CAL-023_D7.fcs · AML_CAL-026_D7.fcs · AML_CAL-027_D7.fcs · AML_CAL-033_D7.fcs · AML_CAL-036_D7.fcs · AML_CVC-002_D7.fcs · AML_CVC-005_D7.fcs · AML_CAL016 (SCAL020)_D7.fcs · AML_CAL043 (SCAL055)_D7.fcs · AML_CAL044 (SCAL056)_D7.fcs · AML_CAU008_D7.fcs · AML_CBH002_D7.fcs · AML_CVC-002_D7.fcs-(1) · AML_CVC001_D7.fcs |
